ArticleAntimicrobial agents and chemotherapy2018
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Prevalence ofFrontiers in microbiology · 2024Pooled it
- Role of Clofazimine in Treatment ofFrontiers in medicine · 2021Pooled it
- A phase therapy regimen containing clofazimine manifested high efficacy in treating Mycobacterium abscessus pulmonary disease.BMC pulmonary medicine · 2026Article
- Bedaquiline combined with clofazimine as salvage therapy for 11 patients with nontuberculous mycobacterial lung disease.BMC infectious diseases · 2025Article
- Current and emerging treatment strategies forEwha medical journal · 2025Review
- Efflux pumps and membrane permeability contribute to intrinsic antibiotic resistance in Mycobacterium abscessus.PLoS pathogens · 2025Article
- Tackling Nontuberculous Mycobacteria by Repurposable Drugs and Potential Leads from Natural Products.Current topics in medicinal chemistry · 2024Review
- TargetingRSC medicinal chemistry · 2023Review
- Drug susceptibility distributions ofAntimicrobial agents and chemotherapy · 2023Article
- Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection.Antimicrobial agents and chemotherapy · 2023Article
- Drug resistance profiles and related gene mutations in slow-growing non-tuberculous mycobacteria isolated in regional tuberculosis reference laboratories of Iran: a three year cross-sectional study.Pathogens and global health · 2023Article
- Non-tuberculous mycobacterial disease: progress and advances in the development of novel candidate and repurposed drugs.Frontiers in cellular and infection microbiology · 2023Review
- Epidemiology of Nontuberculous Mycobacteria in Nanjing andInfection and drug resistance · 2023Article
- Clofazimine as a comparator for preclinical efficacy evaluations of experimental therapeutics against pulmonary M. abscessus infection in mice.Tuberculosis (Edinburgh, Scotland) · 2022Article
- Molecular design of a pathogen activated, self-assembling mechanopharmaceutical device.Journal of controlled release : official journal of the Controlled Release Society · 2022Review
- Article
- Nontuberculous Mycobacterial Resistance to Antibiotics and Disinfectants: Challenges Still Ahead.BioMed research international · 2022Review
- In Vitro Activity and Clinical Outcomes of Clofazimine for Nontuberculous Mycobacteria Pulmonary Disease.Journal of clinical medicine · 2021Article
- Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis.Clinical pharmacokinetics · 2021Review
- Efficacy estimation of a combination of triple antimicrobial agents against clinical isolates ofJAC-antimicrobial resistance · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the natural resistance of nontuberculous mycobacteria (NTM) to many antibiotics, the treatment of diseases caused by NTM is often long-term but unsuccessful. The main goal of this study was to evaluate the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.